The company has committed £279 million ($364 million) to support national efforts aimed at reducing obesity, a critical ...

Chinese insulin maker Gan & Lee Pharmaceuticals is wading into the obesity world with an injectable GLP-1 agonist that beat Novo Nordisk's Ozempic (semaglutide) at lowering glycated hemoglobin (HbA1c) ...

Hoping your company will begin paying for anti-obesity medications like Wegovy? You may be in luck. A growing number of ...

GLP-1 agonists work by triggering the pancreas to produce more insulin, which reduces blood sugar levels in those with type 2 ...

Half of people who develop blood poisoning, otherwise known as sepsis, are dead within a couple of years, a new study finds.

Today's health news includes how the U.S. primary care crisis is hurting the fight against heart disease, the Nobel gender ...

The U.K. is exploring whether obesity drugs could be used to curb joblessness after signing a major investment deal with ...

Experts tell STAT what’s keeping Americans from reaching better cardiovascular health — and what’s giving them hope.

Researchers reveal the importance of personalized communication and side effect management in improving outcomes for patients ...

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...

A surge in the use of GLP-1 drugs is among the reasons a new report projects a calorie intake decline of 10 quadrillion in U.S. adults by 2030.

The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and ...